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The safety and pharmacokinetics of ofloxacin in 48 healthy male volunteers were studied in a two-center,
randomized, double-blind, placebo-controlled study. Ofloxacin (200 or 400 mg) or placebo was administered as
1-h infusions every 12 h for 7 days. Plasma ofloxacin concentrations were measured by high-performance liquid
chromatography. Mean harmonic half-lives ranged from 4.28 to 4.98 h in the 200-mg dosing group and from
5.06 to 6.67 h in the 400-mg dosing group. Intragroup comparisons of trough plasma concentration-versus-time
data from study days 2 through 7 revealed that steady state was achieved by day 2 of both multiple-dose
regimens. Intergroup comparisons of mean harmonic half-lives, the areas under the concentration-time curve
from 0 to 12 and 0 to 60 h, clearance, and apparent volume of distribution (area method) revealed that the
pharmacokinetics of ofloxacin are dose independent. Both ofloxacin dosage regimens appeared to be reasonably
well tolerated. The two dosage regimens of ofloxacin, 200 or 400 mg every 12 h, appear to be safe and provide
serum drug concentrations in excess of the MICs for most susceptible pathogens over the entire dosing interval.
Ofloxacin is a synthetic carboxyquinolone antimicrobial
agent which exhibits broad-spectrum in vitro bactericidal
activities against gram-positive and gram-negative aerobes
(5). The clinical efficacy of ofloxacin has been documented in
patients with respiratory tract, upper and lower urinary
tract, and skin and soft tissue infections and gonococcal and
nongonococcal urethritis (5, 8). In December 1990, the oral
tablet formulation of ofloxacin was approved by the U.S.
Food and Drug Administration, and marketing commenced
in February 1991.
In certain circumstances, such as in patients who are
seriously ill, have ileus, or are nauseated and/or vomiting,
the oral route of ofloxacin administration may not be appro-
priate. In these situations, an intravenous (i.v.) formulation
may prove useful. This study was designed to evaluate the
safety and pharmacokinetics of multiple-dose intravenous
(i.v.) ofloxacin in healthy adult volunteers in two proposed
therapeutic dosing regimens (200 and 400 mg every 12 h
[ql2h]).
MATERIALS AND METHODS
Volunteers. Healthy male volunteers, aged 18 to 40 years
inclusive, participated in the study after granting written,
informed consent as approved by the Human Subjects
Review Committee of Hennepin County Medical Center and
the Institutional Review Board of the Clinical Research
Center, Tulane University School of Medicine. Subjects
were judged to be healthy on the basis of normal findings on
medical history, physical and neurological examinations,
clinical laboratory tests, electroencephalography, and elec-
trocardiography.
Design. This study was conducted as a two-center, double-
blind, randomized placebo-controlled, parallel study, with
* Corresponding author.
t Present address: School of Pharmacy, University of Pittsburgh,
Pittsburgh, PA 15261.
the protocols of 200 and 400 mg ql2h conducted at the
University of Minnesota and Tulane University, respec-
tively. Subjects were randomized to receive either 200 or 400
mg of ofloxacin or identical placebo ql2h as 1-h i.v. infusions
for 7 days. Subjects were confined from 12 h prior to
administration of the first dose until after all final plasma and
urine samples had been collected. Ingestion of caffeine and
alcohol was prohibited during the study period.
The safety tests that were performed included audiometry,
ophthalmology (funduscopy, slit lamp, tonometry, color
vision, acuity), clinical laboratory tests, electrocardiography
(performed prestudy and on days 1, 4, and 8), and electro-
encephalography (performed prestudy and on days 2 and 5).
In addition, urine was screened for crystalluria daily during
treatment, and visual reaction times (assessed by using a
brake reaction timer [American Automobile Association,
Heathrow, Fla.]) were obtained prestudy and on days 1 and
4 of treatment.
Blood samples of 5 ml were obtained from the arm
contralateral to the infusion site immediately prior to the
morning doses on days 1 through 7. In addition, blood
samples were obtained on days 1, 4, and 7 at 0.5 h after the
start of the morning infusion; at the end of the infusion; and
at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 11 h after the end of the
infusion. Blood samples were also obtained 24, 36, 48, and
60 h after the start of the final infusion. Blood samples were
collected in heparinized tubes and centrifuged, and the
plasma was separated and stored frozen at -20°C until it was
assayed.
Specimen analysis. The concentration of ofloxacin in
plasma was determined by a high-pressure liquid chromatog-
raphy method. After extraction at pH 7 with dichlorometh-
ane, the extract was injected onto a C18 ,uBondapak column
(25 cm by 4.6 mm [inner diameter]; Waters Associates Inc.,
Milford, Mass.). The mobile phase consisted of 1.74 g of
potassium dihydrogen phosphate and 20 mg of 1-hexane-
sulfonic sodium salt (Eastman Kodak Co., Rochester, N.Y.)
dissolved in 650 ml of distilled water, combined with 350 ml
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TABLE 1. Subject demographic characteristics
Groupa Age (yr)b (nO. C/B/O)e Ht (cm)b Wt (kg)b
200 mg of ofloxacin 27.2 ± 6.2 (19-37) 9/2/1 181.6 ± 7.4 (170.2-195.6) 77.4 ± 10.2 (60.5-101.8)
200 mg of placebo 27.9 ± 4.5 (21-37) 7/5/0 182.4 ± 7.6 (172.7-193.0) 79.6 ± 12.5 (57.0-98.6)
400 mg of ofloxacin 30.5 ± 5.5 (22-40) 4/7/1 180.6 ± 7.6 (165.1-193.0) 75.4 ± 13.7 (49.1-95.9)
400 mg of placebo 33.3 ± 4.9 (23-38) 10/2/0 176.3 ± 5.8 (167.6-186.7) 75.1 ± 9.0 (60.5-85.0)
a There were 12 subjects in each group.
b Values are means ± standard deviations (ranges).
c C/B/O, Caucasian/black/other.
of methanol and adjusted to pH 3 with phosphoric acid. An
imidazolic analog of ofloxacin (Daiichi Seiyaku) was used as
the internal standard. Detection at 313 nm was done with a
UV detector. The limit of quantitation was 0.01 mg/liter, and
the extraction efficiency was greater than 95%. The assay
was linear over the concentration range of 0.025 to 9
mg/liter. The intra- and interday coefficients of variation
ranged from 3 to 6% over the standard curve concentration
range of 0.025 to 9 mg/liter (2).
Pharmacokinetic analysis. Pharmacokinetic analysis was
done as described previously (3). Areas under the plasma
concentration-versus-time curve from time zero to 12 h
(AUCO_12) on days 1, 4, and 7 and from time zero to 60 h
(AUCO w) on day 7 were determined by trapezoidal integra-
tion. The elimination rate constant (kel) and terminal dispo-
sition half-life (t1/2,) were determined from model fitting of
the 0- to 12-h postdose plasma concentration-versus-time
data to polyexponential equations by using CSTRIP (7)
followed by nonlinear regression analysis using PC NON-
LIN (Statistical Consultants, Lexington, Ky.). Data fits
were unweighted, and the appropriate exponential model
was determined by examining the Akaike information crite-
rion (1, 9), the sum of weighted residuals, and the observed
versus fitted plasma concentration-versus-time data. Each
subjects' day 1, 4, and 7 data fits were analyzed indepen-
dently. Plasma clearance (CL) was calculated by dividing the
dose by AUCO, 12 on days 4 and 7. The apparent volume of
distribution (V) was calculated by dividing CL by k,1.
Statistical analysis. Analysis of variance followed by the
Tukey-Kramer test was performed to determine whether
significant differences occurred between days for the AUC,
keI, CL, and V parameters. Bartlett's test was used to
determine the homogeneity of variance between days for the
AUC, morning trough concentrations (Cmin), kel, CL, and V
parameters. Friedman's test with Page's statistic and Dok-
sum's test with Hollander's statistic were performed to test
for day-to-day differences and trends on the ranked Cmin
values. Comparisons between the ofloxacin and placebo
groups regarding adverse experiences were determined by
using a one-tailed Fisher's exact test. Adverse experience
rates were calculated as the number of subjects with a given
experience divided by the total number of subjects that were
evaluable for safety. All statistical evaluations were per-
formed by using the SAS statistical package (6). Significance
was assessed at the 5% level. Data are presented as means ±
standard deviations unless otherwise noted.
RESULTS
Patient demographics. Demographics of the groups receiv-
ing 200 mg of ofloxacin and placebo at the University of
Minnesota and the groups receiving 400 mg of ofloxacin and
placebo at Tulane University are given in Table 1. Within-
and between-site comparisons of the ofloxacin and placebo
groups from both study sites did not reveal any statistically
significant differences in demographic parameters.
Safety. At the University of Minnesota site, two ofloxacin
recipients were switched to placebo in a blinded fashion
because of adverse events. One of these subjects developed
a fine macular erythematous rash on his back and front torso
during the morning dose on study day 4; the rash resolved
spontaneously after the switch to placebo. The other subject
developed dizziness and tachycardia as well as erythema and
pruritus at the i.v. infusion site during the initial infusion;
these adverse events also resolved spontaneously after the
switch to placebo. All recipients of 200 mg of placebo
completed the study. Overall, 8 of 12 subjects who received
200 mg of ofloxacin and 8 of 12 subjects who received
placebo experienced adverse events during the study. A
total of 49 and 32 adverse events were reported in the
ofloxacin and placebo recipients, respectively. These were
the totals of all reactions independent of the degree of
association to study therapy. Adverse events (number of
subjects in parentheses) in the ofloxacin group included
extremity pain (n = 1), dizziness (n = 1), headache (n = 2),
paresthesia (n = 1), ocular dryness (n = 1), ocular redness (n
= 1), edema (n = 1), tachycardia (n = 1), abnormal chest
sounds (n = 1), diarrhea (n = 5), urinary incontinence (n =
1), skin erythema (n = 2), rash (n = 1), and i.v. infusion site
skin reaction (n = 30). Adverse events in the placebo group
included chills (n = 1), trunk pain (n = 1), extremity pain (n
= 2), headache (n = 1), syncope (n = 1), edema (n = 2),
gastrointestinal cramps (n = 2), gastrointestinal distress (n =
1), diarrhea (n = 3), skin lesions (n = 1), skin erythema (n =
3), and i.v. infusion site skin reaction (n = 14). There were
no statistically significant differences between the ofloxacin
and placebo groups in terms of vital signs at baseline or mean
changes. No subjects in either group developed neurological
abnormalities during the study. No clinically significant
alterations in ophthalmologic, audiometric, electrocardio-
graphic, electroencephalographic, or clinical laboratory tests
were noted in either group over the course of the study. In
addition, there were no statistically significant within-group
or between-group differences in visual reaction times (data
not shown).
At the Tulane University site, all 24 enrolled subjects (12
who received ofloxacin, 12 who received placebo) completed
participation in the study. Overall, 5 of 12 subjects who
received 400 mg of ofloxacin and 3 of 12 subjects who
received placebo experienced adverse events during the
study. A total of 16 and 8 events were reported in the
ofloxacin and placebo recipients, respectively. As stated
above, these totals were independent of the degree of
association to study therapy. Adverse events in the ofloxacin
group included dizziness (n = 1), headache (n = 1), otalgia (n
= 1), vasodilation (n = 2), pharyngitis (n = 1), constipation
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FIG. 1. Mean ± standard deviation plasma ofloxacin concentration-versus-time profiles following single and multiple 200-mg ql2h i.v.
dose administration in normal volunteers.
(n = 1), keratoderma (n = 1), rash (n = 1), i.v. infusion site
skin reaction (n = 5), diaphoresis (n = 1), and muscle
stiffness (n = 1). Adverse events in the placebo group
included dizziness (n = 1), tremor (n = 1), dream abnormal-
ity (n = 1), dyspnea (n = 1), pharyngitis (n = 1), rash (n =
2), and arthralgia (n = 1). As in the University of Minnesota
subjects, there were no statistically or clinically significant
alterations in ophthalmologic, audiometric, electrocardio-
graphic, electroencephalographic, clinical laboratory, or vi-
sual reaction time tests in either study group.
The discrepancies in i.v. infusion site skin reaction rates
between the two study sites may have been due to the racial
imbalance in study populations between the study sites. At
the University of Minnesota site, the major i.v. infusion site
skin reaction in both study groups was erythema (15 of 30
reactions in ofloxacin recipients, 11 of 14 reactions in pla-
cebo recipients), which occurred in a predominantly Cauca-
sian study population. Perhaps the predominance of blacks
at the Tulane University site made assessment of erythema
as a reaction more difficult, leading to the much lower i.v.
infusion site reaction incidence noted at that site.
Pharmacokinetics. The mean plasma concentration-ver-
sus-time curves for the 200- and 400-mg ql2h multiple-dose
groups are illustrated in Fig. 1 and 2, respectively. The
pharmacokinetic parameters for both dosing groups are
given in Table 2. Ofloxacin plasma concentration-versus-
time data were best fit by a two-compartment open model in
all subjects. The harmonic mean t1/2 for days 1, 4, and 7 for
the 200-mg group (4.28, 4.91, and 4.98 h, respectively) and
400-mg group (5.06, 6.00, and 6.67 h, respectively) were
comparable intradose and interdose (P was not significant
for all comparisons). Comparable results were obtained
when examining intradose and interdose CL and V data.
Steady state was achieved by day 2 in both dosing groups, as
evidenced by the nonsignificant differences in Cmin from
study days 2 to 7 (Fig. 3). Intradose comparisons of AUCO12
data in both the 200-mg (AUCO, 12 day 4 = 12.96 ± 1.62
mg * h/liter versus AUCO_12 day 7 = 12.71 + 1.34 mg. h/
liter; P was not significant) and 400-mg (AUCO_12 day 4 =
30.17 ± 6.26 mg. h/liter versus AUCO12 day 7 = 28.99 +
6.98 mg- h/liter; P was not significant) groups corroborated
the results of the Cmin data analysis. Interdose comparisons
of the AUCO_12 on days 1, 4, and 7 and the AUCO-60 on day
7 revealed that the values for the recipients of 400 mg were
not statistically significantly different from double the re-
spective values for the recipients of 200 mg. Statistical
analysis revealed no significant race-related differences in
AUC, t1/2., CL, or V, even when logistic regression was
used to examine the dose-race interaction.
Mean
Cone.
(mg/L)
4 6 8 10 12
7-
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4-
3-
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I
0 I I I
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4I I I I
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FIG. 2. Mean ± standard deviation plasma ofloxacin concentration-versus-time profiles following single and multiple 400-mg ql2h i.v.
dose administration in normal volunteers.
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FIG. 3. Mean± standard deviation plasma morning trough
ofloxacin concentrations over time following multiple 200-mg (A)
and 400-mg (0)qg2h i.v. dose administration in normal volunteers.
001+ 0I *C
1+ DISCUSSION
The single-dose i.v. pharmacokinetic parameters obtained
in this study were comparable to those reported previously
n in normal subjects (4, 10). In the study of Lode and cowork-
CD:<>mers (4),dtin, ranged from 3.9±rtn0.6 to 4.5±C0.6 h, AUCnV
_ suggest(comparable to AUCOi12 for days 4 and 7 in the present
0_ O kinestudy) ranged from 1.5±0.2 to 14.4r 1.8mgia h/liter, CL0
'~~~~' ~~~ranged from 14.0 ± 1.7 to 17.2 ± 2.0 liters/h, and V ranged00~~~~~~CC, from 863 10 to 103±32 liters for single i.v. doses ranging
ol from 25to200mg. Yuk andscoworkers (10)reportedta2l of
R CD>5.71 ± 0.73 h, Vof 132 ± 19 liters, CL of 15.6 ± 3.0 liters/h,
CD c and AUCie,nof 27.1 ± 4.11mg h/liter after a single 400-mg
,00-< 3
,
°rcisWeeterunoi.ifsnieki.v.dos
The present study extends these previous observations to
I+ dinclude multiple-dose i.v. administration. Data from this
6,,>:.g> thisstudy demonstrate that steady state is achieved by day 2 of
a multiple dose i.v. ofloxacin regimen in normal volunteers.
J;-.5CA riQ In addition, interdose comparisons oft12sb, AUC, CL, and V
suggest that ofloxacin exhibits dose-independent pharmaco-
_
kinetics over the dosage range studied. Similar dose-inde-
0 0 pagendent pharmacokinetics over a lower i.v. dosage range (25
" 1+: 90% ofisolates,1+ to 200 mg) were demonstrated by Lode et al. (4).
°|+0l substParenteral ofloxacin appeared to be reasonably well toler-(A°°° ated in recipients of the two dosage regimens studied, with
the exception of a high incidence of i.v. infusion site skin
0:£_ sreactions. Whether the frequency of i.v. infusion site skin
~c 00 0 reactions can be reduced by prolonging the infusion time or
*001** *
~~~-_
~~~~diluting the drug concentration from the 2 to 4 mg/ml used in
this study warrants further investigation. In any case, oflox-
_ > maci should be administered via the oral route whenever
possible to avoid this potential complication.
-J 00 ~ .Results of this study demonstrate that parenteral ofloxacin
00 in dosage regimens of 200 and 400 mg ql2h provides con-
- I.centrations in serum in excess of the MICs for most suscep-
~~,~,~~~-~~ tible pathogens (MIC for 90% of isolates, <0.5 to 1 mg/liter)
over the entire dosing interval. However, for less susceptible
o o~~~0pathogens such as Pseudomonas aeruginosa (MIC range for
90% of isolates, 1 to 8 mg/liter), such regimens may provide
RRCDn ~~~~~substantial periods of time that the drug is present at1~~~=15n~~~~concentrations below the MIC for the organism. Further
orio ~~~~~~~studies of higher or more frequently administered i.v. doses
may be warranted.
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